The FDA has approved a 0.5mg capsule formulation of Aloxi (palonosetron hydrochloride, from Eisai and Helsinn) for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Aloxi, a 5-HT₃ receptor antagonist, is already available as a 0.25mg IV injection for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy and for the prevention of acute nausea and vomiting associated with initial and repeat course of highly emetogenic chemotherapy. Aloxi 0.075mg injection is approved for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

For more information call (888) 422-4743 or visit www.aloxi.com.